A retrospective analysis comparing APCEDEN dendritic cell immunotherapy with best supportive care in refractory cancer.
作者信息
Kumar Chaitanya, Kohli Sakshi, Chiliveru Srikanth, Bapsy Poonamalle Parthasarathy, Jain Minish, Suresh Attili Venkata Sathya, Mohan Jagan, Vaid Ashok K, Sharan Bandana
机构信息
APAC Biotech Pvt Ltd, Gurgaon, India.
Department of Oncology, Apollo Hospital, Bangalore, India.
出版信息
Immunotherapy. 2017 Sep;9(11):889-897. doi: 10.2217/imt-2017-0064. Epub 2017 Aug 25.
AIM
A retrospective survival benefit analysis of APCEDEN, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in comparison with a control group.
METHODS
Subjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for analysis.
RESULTS
The analysis suggests a significant survival benefit of 199 days for the APCEDEN therapy treatment group when compared with the control group (356 vs 157 days). The event-free survival time of APCEDEN therapy was 439 days in patients who demonstrated an objective response at first evaluation as per immune-related response criteria.
CONCLUSION
APCEDEN demonstrated highly convincing survival benefits when compared with the control group.
Zotero 插件